Literature DB >> 23390096

Trophic factor gene therapy for Parkinson's disease.

Jeffrey H Kordower1, Anders Bjorklund.   

Abstract

Parkinson's disease (PD) is a chronic and progressive neurodegenerative movement disorder for which there is presently no cure. Pharmacological remedies targeting the dopaminergic network are relatively effective at ameliorating motor deficits, especially in the early stages of the disease, but none of these therapies are curative and many generate their own problems. Recent advances in PD research have demonstrated that gene delivery of trophic factors, glial cell line-derived neurotrophic factor (GDNF) and neurturin, in particular, can provide structural and functional recovery in rodent and nonhuman primate models of PD. Similar success has been gleaned in open-label clinical trials, although this has yet to be realized in double-blinded analyses. This work reviews the field of trophic factor gene delivery for PD.
Copyright © 2013 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390096     DOI: 10.1002/mds.25344

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

Review 1.  Gene-based therapies in Parkinson's disease.

Authors:  Patricia J Allen; Andrew Feigin
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects.

Authors:  Kai-C Sonntag; Bin Song; Nayeon Lee; Jin Hyuk Jung; Young Cha; Pierre Leblanc; Carolyn Neff; Sek Won Kong; Bob S Carter; Jeffrey Schweitzer; Kwang-Soo Kim
Journal:  Prog Neurobiol       Date:  2018-04-11       Impact factor: 11.685

Review 3.  Gene therapy for Parkinson's disease: still a hot topic?

Authors:  Jeffrey H Kordower
Journal:  Neuropsychopharmacology       Date:  2015-01       Impact factor: 7.853

4.  Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.

Authors:  Ian F Harrison; William R Crum; Anthony C Vernon; David T Dexter
Journal:  Br J Pharmacol       Date:  2015-07-08       Impact factor: 8.739

5.  Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Authors:  Silke Nuber; Daniel Tadros; Jerel Fields; Cassia Rose Overk; Benjamin Ettle; Kori Kosberg; Michael Mante; Edward Rockenstein; Margarita Trejo; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-08       Impact factor: 17.088

6.  There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease.

Authors:  P R Lowenstein; Viveka Nand Yadav; Peter Chockley; Maria Castro
Journal:  Mol Ther       Date:  2014-02       Impact factor: 11.454

7.  Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.

Authors:  Durga Praveen Meka; Anne Kathrin Müller-Rischart; Prakash Nidadavolu; Behnam Mohammadi; Elisa Motori; Srinivas Kumar Ponna; Helia Aboutalebi; Mahmoud Bassal; Anil Annamneedi; Barbara Finckh; Margit Miesbauer; Natalie Rotermund; Christian Lohr; Jörg Tatzelt; Konstanze F Winklhofer; Edgar R Kramer
Journal:  J Clin Invest       Date:  2015-03-30       Impact factor: 14.808

8.  Do subjects with minimal motor features have prodromal Parkinson disease?

Authors:  Yaping Chu; Aron S Buchman; C Warren Olanow; Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2018-03-10       Impact factor: 10.422

9.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

Review 10.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.